Page 149 - 89Zr-Immuno-PET:Towards a Clinical Tool to Guide Antibody-based Therapy in Cancer

Table 1 Patient characteristics
Patient Gender Age
1 M 23
2 F 55
3 M 46
4 M 46
5 M 47
6 F 69
Response to first line
complete remission partial remission complete remission
complete remission complete remission partial remission
Ann Arbor stage at relapse
IV A III B III B
II A IE III A
Disease localization
at relapse on 18F-FDG-PET
liver
cervical, para-iliac, spleen
supraclavicular, mediastinal, hilar, mesenteric, retro-peritoneal, para-iliac, inguinal
retro-peritoneal nasopharynx
submandibular, retro-clavicular, axillar, inguinal
Administration of 89Zr-rituximab was well tolerated by all patients. Four patients underwent all scans according to protocol. Due to chemotherapy induced nausea, only a scan of the head and neck area could be obtained in patient 2, and blood sampling at D3 and 6 was not feasible. Patient 6 cancelled the D3 scan due to diarrhea and nausea, most likely caused by an infectious entero-colitis. For patient 3 no venous blood sample was obtained at D3.
89Zr-rituximab in blood pool, liver, spleen and kidneys was evident at D0, decreasing over time in all patients (Figure 1).
7
89Zr-rituximab-PET in lymphoma
Figure 1 Example of whole body distribution of 89Zr-rituximab over time Maximum intensity projections at D0, D3 and D6 p.i. for patient 3.
147